Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. (29th May 2018)

• Record Type: Journal Article
• Authors: McLornan, Donal P.; Szydlo, Richard; Robin, Marie; van Biezen, Anja; Koster, Linda; Blok, Henrik J. P.; Van Lint, Maria T.; Finke, Jürgen; Vitek, Antonin; Carlson, Kristina; Griskevicius, Laimonas; Holler, Ernst; Itälä‐Remes, Maija; Schaap, Michel; Socié, Gerard; Bay, Jacques‐Olivier; Beguin, Yves; Bruno, Benedetto; Cornelissen, Jan J.; Gedde‐Dahl, Tobias; Ljungman, Per; Rubio, Marie T.; Yakoub‐Agha, Ibrahim; Klyuchnikov, Evgeny; Olavarria, Eduardo; Chalandon, Yves; Kröger, Nicolaus
• Is Part Of: British journal of haematology. Volume 182:Number 3(2018)
• Page Start: 418
• Page End: 422
• Publication Date: 2018-05-29
• Subjects: mylelofibrosis -- allogeneic stem cell transplant -- fibrosis -- JAK inhibitors -- relapse; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15407
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Allogeneic Haematopoietic Stem Cell Transplant (allo‐HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo‐HSCT for MF.